Nuveen Asset Management LLC increased its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 595,581 shares of the company's stock after purchasing an additional 14,792 shares during the quarter. Nuveen Asset Management LLC owned about 0.93% of MoonLake Immunotherapeutics worth $32,251,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in the stock. FMR LLC grew its position in shares of MoonLake Immunotherapeutics by 28.1% in the fourth quarter. FMR LLC now owns 6,341,391 shares of the company's stock valued at $343,386,000 after purchasing an additional 1,391,167 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of MoonLake Immunotherapeutics by 12.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,343,643 shares of the company's stock valued at $181,059,000 after purchasing an additional 363,394 shares in the last quarter. Federated Hermes Inc. grew its position in shares of MoonLake Immunotherapeutics by 13.2% in the fourth quarter. Federated Hermes Inc. now owns 1,280,052 shares of the company's stock valued at $69,315,000 after purchasing an additional 149,724 shares in the last quarter. Marshall Wace LLP grew its stake in MoonLake Immunotherapeutics by 7.9% during the fourth quarter. Marshall Wace LLP now owns 1,245,299 shares of the company's stock valued at $67,433,000 after acquiring an additional 90,914 shares in the last quarter. Finally, Alliancebernstein L.P. grew its stake in MoonLake Immunotherapeutics by 2.5% during the fourth quarter. Alliancebernstein L.P. now owns 1,022,604 shares of the company's stock valued at $55,374,000 after acquiring an additional 24,464 shares in the last quarter. 93.85% of the stock is currently owned by hedge funds and other institutional investors.
MoonLake Immunotherapeutics Price Performance
MLTX stock opened at $38.54 on Thursday. MoonLake Immunotherapeutics has a one year low of $31.42 and a one year high of $58.26. The stock has a market cap of $2.47 billion, a PE ratio of -29.88 and a beta of 1.31. The firm has a 50 day simple moving average of $38.45 and a two-hundred day simple moving average of $44.58.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.63) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.13. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. On average, research analysts expect that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.
Analysts Set New Price Targets
MLTX has been the subject of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Thursday, February 27th. Royal Bank of Canada initiated coverage on shares of MoonLake Immunotherapeutics in a research note on Tuesday, March 18th. They set an "outperform" rating and a $67.00 price objective for the company. Wolfe Research raised shares of MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price objective for the company in a research note on Monday. Wedbush restated an "outperform" rating and set a $80.00 target price (up from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Finally, The Goldman Sachs Group reduced their target price on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a research report on Thursday, February 27th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $78.71.
Check Out Our Latest Research Report on MoonLake Immunotherapeutics
About MoonLake Immunotherapeutics
(
Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
